This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Rhinosinusistis is increasing in prevalence and incidence, and has been estimated to affect approximately 31 million patients in the United States each year. It causes significant physical symptoms, negatively affects quality of life, and can be substantially impair daily functioning. Nasal steroids are the mainstay of treatment, although not all patients with chronic rhinosinusitis improve with nasal steroids. Pulmicort Respules consist of a sterile suspension for inhalation via jet nebulizer and contain the active ingredient budesonide. It is believed that the nebulized delivery system leads to better treatment response than standard nasal steroid preparations. According to information contained in the PDR, total absolute bioavailability (ie, lung + oral) in asthmatic children following pulmonary administration of Pulmicort Respules via jet nebulizer was approximately 6% of the labeled dose. The peak plasma concentration of budesonide occurred 10-30 minutes after start of nebulization. The amount of budesonide absorbed following nasal application is known. The goal of this study is to assess whether nasal administration of Pulmicort Respules for 30 days results in suppression of adrenal function as a result of systemic absorption. Twenty adult patients with chronic rhinosinusitis, with or without nasal polyps, will be enrolled over a 12-month period. Patients will have cortisol levels determined before and 30 minutes after administration of cosyntropin (ie., cosyntropin test). The cosytropin test will be performed twice during the study. The first time will be at the initiation of Pulmicort respules and the second time will be 30 days aftewr Pulmicort respules on a daily basis. The primary outcome measure will be the absolute cortisol number stimulated after 30 days of Pulmicort respule therapy. This will be calculated as the difference between the cortisol number before cosyntropin injection and the number after cosyntropin injection. Secondary outcome measures will include baseline and 30-day cortisol value before cosyntropin administration.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000036-46
Application #
7377222
Study Section
Special Emphasis Panel (ZRR1-CR-4 (02))
Project Start
2006-04-01
Project End
2007-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
46
Fiscal Year
2006
Total Cost
$4,582
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Arslanian, Silva; El Ghormli, Laure; Kim, Joon Young et al. (2018) The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in ?-Cell Function in TODAY. Diabetes Care :
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44
Venditti, E M; Tan, K; Chang, N et al. (2018) Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes. Diabetes Res Clin Pract 139:24-31
Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Bertozzi, Beatrice; Tosti, Valeria; Fontana, Luigi (2017) Beyond Calories: An Integrated Approach to Promote Health, Longevity, and Well-Being. Gerontology 63:13-19
Arslanian, Silva; El Ghormli, Laure; Bacha, Fida et al. (2017) Adiponectin, Insulin Sensitivity, ?-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY. Diabetes Care 40:85-93
Obermeit, Lisa C; Beltran, Jessica; Casaletto, Kaitlin B et al. (2017) Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining ""symptomatic"" versus ""asymptomatic"" HAND. J Neurovirol 23:67-78

Showing the most recent 10 out of 497 publications